Gene · 6921
Papers1,693
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 1,693
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Radiogenomics in Renal Cancer Management-Current Evidence and Future Prospects. | Int J Mol Sci | 2023 | 36902045 | PubTator, text mining | PubMed |
| Analysis of Wild Type and Variant B Cystatin C Interactome in Retinal Pigment Epithelium Cells Reveals Variant B Interacting Mitochondrial Proteins. | Cells | 2023 | 36899848 | PubTator, text mining | PubMed |
| Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I. | Viruses | 2023 | 36851677 | PubTator, text mining | PubMed |
| Preparing a database of corrected protein structures important in cell signaling pathways. | Res Pharm Sci | 2023 | 36846730 | PubTator, text mining | PubMed |
| Our Current Understanding of the Heterogeneity in Prostate Cancer and Renal Cell Carcinoma. | J Clin Med | 2023 | 36836061 | PubTator, text mining | PubMed |
| Role of SOCS and VHL Proteins in Neuronal Differentiation and Development. | Int J Mol Sci | 2023 | 36835292 | PubTator, text mining | PubMed |
| Two Single Nucleotide Polymorphisms in the Von Hippel-Lindau Tumor Suppressor Gene in Patients with Clear Cell Renal Cell Carcinoma. | Int J Mol Sci | 2023 | 36835190 | PubTator, text mining | PubMed |
| Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. | Cancers (Basel) | 2023 | 36831657 | PubTator, text mining | PubMed |
| E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology. | J Med Chem | 2023 | 36821822 | PubTator, text mining | PubMed |
| Big data in corneal diseases and cataract: Current applications and future directions. | Front Big Data | 2023 | 36818823 | PubTator, text mining | PubMed |
| Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic KAT6A::NRG1 fusion on Ipilimumab- Nivolumab immunotherapy. A case study and review of the literature. | Front Oncol | 2023 | 36816927 | PubTator, text mining | PubMed |
| E3 ligase autoinhibition by C-degron mimicry maintains C-degron substrate fidelity. | Mol Cell | 2023 | 36805027 | Swiss-Prot, curated | PubMed |
| SOCS7-Derived BC-Box Motif Peptide Mediated Cholinergic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells. | Int J Mol Sci | 2023 | 36769102 | PubTator, text mining | PubMed |
| A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC. | Cancers (Basel) | 2023 | 36765892 | PubTator, text mining | PubMed |
| The structural basis for HIV-1 Vif antagonism of human APOBEC3G. | Nature | 2023 | 36754086 | Swiss-Prot, curated | PubMed |
| The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma. | Mol Cancer Res | 2023 | 36753617 | PubTator, text mining | PubMed |
| VHL-HIF-2α axis-induced SEMA6A upregulation stabilized β-catenin to drive clear cell renal cell carcinoma progression. | Cell Death Dis | 2023 | 36739418 | PubTator, text mining | PubMed |
| Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy. | Adv Sci (Weinh) | 2023 | 36737841 | PubTator, text mining | PubMed |
| Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. | Mol Cell | 2023 | 36736316 | PubTator, text mining | PubMed |
| Computational approaches for the design of modulators targeting protein-protein interactions. | Expert Opin Drug Discov | 2023 | 36715303 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6921/papers?page=10